Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gideon Bollag

Showing results (71-80 of 84) with videos related to

Pageof 9
Sort By:
Cancer Discovery|April 8, 2015
Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 "Gatekeeper" F691L Mutation with PLX3397Catherine C Smith, Chao Zhang, Kimberly C Lin, et al.
Gynecologic Oncology|March 23, 2023
Uterine leiomyosarcomas harboring MAP2K4 gene amplification are sensitive in vivo to PLX8725, a novel MAP2K4 inhibitorBlair McNamara, Justin Harold, Diego Manavella, et al.
JCI Insight|July 27, 2018
The RUNX1/IL-34/CSF-1R axis is an autocrinally regulated modulator of resistance to BRAF-V600E inhibition in melanomaOrsi Giricz, Yongkai Mo, Kimberly B Dahlman, et al.
Nature|October 16, 2015
RAF inhibitors that evade paradoxical MAPK pathway activationChao Zhang, Wayne Spevak, Ying Zhang, et al.
JAMA Oncology|July 8, 2021
Association of Combination of Conformation-Specific KIT Inhibitors With Clinical Benefit in Patients With Refractory Gastrointestinal Stromal Tumors: A Phase 1b/2a Nonrandomized Clinical TrialAndrew J Wagner, Paul L Severson, Anthony F Shields, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 10, 2013
Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanomaKerstin Trunzer, Anna C Pavlick, Lynn Schuchter, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 1, 2009
Scaffold-based discovery of indeglitazar, a PPAR pan-active anti-diabetic agentDean R Artis, Jack J Lin, Chao Zhang, et al.
Neuro-Oncology|July 5, 2022
MEK inhibitors for neurofibromatosis type 1 manifestations: Clinical evidence and consensusPeter M K de Blank, Andrea M Gross, Srivandana Akshintala, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 22, 2008
Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activityJames Tsai, John T Lee, Weiru Wang, et al.
Nature|September 9, 2010
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanomaGideon Bollag, Peter Hirth, James Tsai, et al.
Pageof 9

Showing results (71-80 of 84) with videos related to

Sort By:
Pageof 9
Cancer Discovery|April 8, 2015
Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 "Gatekeeper" F691L Mutation with PLX3397Catherine C Smith, Chao Zhang, Kimberly C Lin, et al.
Gynecologic Oncology|March 23, 2023
Uterine leiomyosarcomas harboring MAP2K4 gene amplification are sensitive in vivo to PLX8725, a novel MAP2K4 inhibitorBlair McNamara, Justin Harold, Diego Manavella, et al.
JCI Insight|July 27, 2018
The RUNX1/IL-34/CSF-1R axis is an autocrinally regulated modulator of resistance to BRAF-V600E inhibition in melanomaOrsi Giricz, Yongkai Mo, Kimberly B Dahlman, et al.
Nature|October 16, 2015
RAF inhibitors that evade paradoxical MAPK pathway activationChao Zhang, Wayne Spevak, Ying Zhang, et al.
JAMA Oncology|July 8, 2021
Association of Combination of Conformation-Specific KIT Inhibitors With Clinical Benefit in Patients With Refractory Gastrointestinal Stromal Tumors: A Phase 1b/2a Nonrandomized Clinical TrialAndrew J Wagner, Paul L Severson, Anthony F Shields, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 10, 2013
Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanomaKerstin Trunzer, Anna C Pavlick, Lynn Schuchter, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 1, 2009
Scaffold-based discovery of indeglitazar, a PPAR pan-active anti-diabetic agentDean R Artis, Jack J Lin, Chao Zhang, et al.
Neuro-Oncology|July 5, 2022
MEK inhibitors for neurofibromatosis type 1 manifestations: Clinical evidence and consensusPeter M K de Blank, Andrea M Gross, Srivandana Akshintala, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 22, 2008
Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activityJames Tsai, John T Lee, Weiru Wang, et al.
Nature|September 9, 2010
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanomaGideon Bollag, Peter Hirth, James Tsai, et al.
Pageof 9